$CPAY

Corpay (CPAY) holder files to resell NYSE-traded common stock via UBS

Corpay, Inc. (CPAY) filed a Form 144 notice to resell NYSE-traded common stock through UBS Financial Services Inc., according to the filing. The notice also lists prior restricted stock award acquisitions from the issuer on 01/22/2025 (1,102 shares), 01/23/2024 (1,497), 01/01/2016 (408), and 05/04/2017 (2,293).

Original reporting
Published Aug 12, 2026, 8:40 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 13, 2026, 4:25 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefFinancial news
Primary signal
$CPAY
Neutral
low confidence
Mentioned
$CPAY
Relevance
4/10
alphai data visualization · based on stocktitan.net
Decision brief

The 30-second read

$CPAYNeutralLow
01

Why it matters

Traders may monitor CPAY for potential incremental selling pressure, but the provided excerpt lacks key execution details (planned resale size and timing), limiting conviction.

02

Market read

This is a regulatory resale disclosure that may modestly affect short-term supply expectations for CPAY, without evidence of a fundamental change.

03

What to watch

Actual market impact depends on the total number of shares proposed for resale, the holder’s remaining lockups, and whether the resale is executed in tranches.

Relevance 4/10Novelty 4/10Timing: Form 144 resale notice filed, potentially relevant for near-term supply expectations

Background

The article summarizes a Form 144 notice for Corpay common stock resale through UBS Financial Services Inc., referencing prior restricted stock award acquisitions.

Company-level read

Ticker impact

$CPAYNeutralLow confidence
Context

Corpay filed a Form 144 notice to resell NYSE-traded common stock through UBS, tied to prior restricted stock awards.

Expected impact

Low likelihood of a large immediate move from this filing alone; any impact would be gradual and dependent on actual resale size and execution.

Evidence & confidence

The text confirms a proposed resale via UBS and lists prior RSA acquisition dates, but it does not disclose the total shares to be sold, the resale window, or any new operational/financial catalyst.

Market effects

Limited sector read-through; this is a company-specific resale filing rather than an industry catalyst.

No clear regional spillover beyond NYSE-traded CPAY liquidity.

No global macro or cross-border transaction details provided.

Counterpoint

The filing may reflect routine insider/employee liquidity after vesting, with no meaningful incremental selling pressure if the resale size is small or already hedged.

Key entities

  • Corpay, Inc.

    NYSE-traded company whose common stock is subject to a proposed resale notice on Form 144.

  • UBS Financial Services Inc.

    Broker-dealer through which the proposed resale is arranged.

  • Form 144

    SEC resale notice used to provide transparency when restricted securities are proposed for sale.

Related articles

$CPAYMed

Corpay (CPAY) Just Posted A Record Quarter, So Why The Caution?

Corpay (NYSE:CPAY) reported Q2 2026 revenue of $1.34 billion, up 21% year over year and $45 million above expectations, with cash EPS of $7.00, up 36%. The company raised full-year guidance to $5.31 billion revenue and $27.35 cash EPS midpoint, citing growth in Corporate and Vehicle Payments, plus Alpha and Avid contributions, while noting a $100 million FTC-related charge and an Epics divestiture.

$CPAYMedAI 8/10

Corpay (CPAY) Q2 2026 Earnings Call Transcript

Corpay (NYSE:CPAY) reported Q2 2026 revenues of $1.34B, up 21%, and adjusted net income per diluted share of $7.00, up 36% year over year. Management guided FY2026 revenue to $5.29B-$5.33B and adjusted EPS to $27.15-$27.55, plus FCF of about $1.8B. The quarter included a $100M FTC settlement charge and $321M in share repurchases.

$CPAYHighAI 9/10

Corpay Q2 Earnings Call Highlights

Corpay (NYSE:CPAY) raised full-year revenue guidance to $5.31B at the midpoint (+17% vs 2025) and adjusted EPS to $27.35 (+28%). Q2 results included a $45M revenue beat; guidance reflects improved macro and momentum, partly offset by an epyx sale expected to close in fall. Q3 revenue midpoint is $1.355B, adjusted EPS $7.15.

$CPAYMedAI 8/10

Corpay: Q2 Earnings Snapshot

Corpay, Inc. (CPAY) reported Q2 net income of $248.3 million, or $3.70 per share. Adjusted earnings were $7.00 per share versus a Zacks estimate of $6.60. Revenue was $1.34 billion versus $1.31 billion expected. Corpay forecast full-year earnings of $27.15 to $27.55 per share and revenue of $5.29 to $5.33 billion.